In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma.

ABSTRACT:

Background

For angioimmunoblastic T cell lymphoma (AITL), a rare cancer, no specific treatments are available and survival outcome is poor. We previously developed a murine model for AITL that mimics closely human disease and allows to evaluate new treatments. As in human AITL, the murine CD4⁺ follicular helper T (Tfh) cells are drivers of the malignancy. Therefore, chimeric antigen receptor (CAR) T cell therapy might represent a new therapeutic option.

Methods

To prevent fratricide among CAR T cells when delivering an CD4-specific CAR, we used a lentiviral vector (LV) encoding an anti-CD4 CAR, allowing exclusive entry into CD8 T cells.

Results

These anti-CD4CAR CD8-targeted LVs achieved in murine AITL biopsies high CAR-expression levels in CD8 T cells. Mal

SUBMITTER: Krug A 

PROVIDER: S-EPMC11401350 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature